News | Gore Medical

GORE^® TAG^® THORACIC BRANCH ENDOPROSTHESIS (TBE) NOW INDICATED FOR ZONE 0 AND ZONE 1 AORTIC ARCH REPAIRS

The first off-the-shelf, on-label branched endovascular device for Zones 0, 1 and 2.

GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System Products on a White Background

GORE ANNOUNCES FDA APPROVAL AND FIRST COMMERCIAL IMPLANT OF LARGE-DIAMETER THORACIC TAPERS

New tapered sizes broaden treatment options for patients with thoracic aortic disease states.

FIRST COMMERCIAL IMPLANT OF THE GORE^® EXCLUDER^® CONFORMABLE AAA ENDOPROSTHESIS WITH ACTIVE CONTROL SYSTEM IN CANADA

Bringing physicians a new degree of control and conformability

Gore releases 3-year data for the GORE^® CARDIOFORM ASD Occluder

Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success^*

NOW INDICATED FOR AAA PATIENTS WITH HIGHLY ANGULATED NECKS

W. L. Gore & Associates (Gore) announces FDA approval of an expanded indication for the GORE^®...

W. L. GORE & ASSOCIATES, INC. RECEIVES U.S. FOOD & DRUG ADMINISTRATION (FDA) APPROVAL FOR LOWER PROFILE GORE^® VIABAHN^® VBX BALLOON EXPANDABLE ENDOPROSTHESIS, NOW 6 FR SHEATH COMPATIBLE

With improvements to the stent graft delivery system enabling a 1 Fr profile reduction on the...

GORE RECEIVES FDA APPROVAL FOR BREAKTHROUGH ENDOVASCULAR DEVICE IN COMPLEX AORTIC ANEURYSMS

First off-the-shelf solution for treatment of complex aneurysmal disease involving the visceral...

FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY

This study aims to compare the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis primary...

GORE ANNOUNCES FIRST PATIENT IMPLANT IN THE ARISE II PIVOTAL STUDY OF THE GORE^® ASCENDING STENT GRAFT

The first patient implant in the ARISE II Pivotal Study evaluation of the GORE® Ascending Stent...

THE GORE RELIEF CLINICAL STUDY BEGINS RANDOMIZING PATIENTS TO EVALUATE PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF

The Gore RELIEF Clinical Study is evaluating the safety and efficacy of transcatheter closure of...

Media Contacts

Jessica Moran
Arizona, United States
+1 480 601 4799
jmoran@wlgore.com

Henrietta Bryan
United Kingdom
+44 (0) 7867 90 6287
hbryan@wlgore.com

GORE® TAG® THORACIC BRANCH ENDOPROSTHESIS (TBE) NOW INDICATED FOR ZONE 0 AND ZONE 1 AORTIC ARCH REPAIRS

GORE ANNOUNCES FDA APPROVAL AND FIRST COMMERCIAL IMPLANT OF LARGE-DIAMETER THORACIC TAPERS

FIRST COMMERCIAL IMPLANT OF THE GORE® EXCLUDER® CONFORMABLE AAA ENDOPROSTHESIS WITH ACTIVE CONTROL SYSTEM IN CANADA

Gore releases 3-year data for the GORE® CARDIOFORM ASD Occluder

NOW INDICATED FOR AAA PATIENTS WITH HIGHLY ANGULATED NECKS

W. L. GORE & ASSOCIATES, INC. RECEIVES U.S. FOOD & DRUG ADMINISTRATION (FDA) APPROVAL FOR LOWER PROFILE GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS, NOW 6 FR SHEATH COMPATIBLE

GORE RECEIVES FDA APPROVAL FOR BREAKTHROUGH ENDOVASCULAR DEVICE IN COMPLEX AORTIC ANEURYSMS

FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY

GORE ANNOUNCES FIRST PATIENT IMPLANT IN THE ARISE II PIVOTAL STUDY OF THE GORE® ASCENDING STENT GRAFT

THE GORE RELIEF CLINICAL STUDY BEGINS RANDOMIZING PATIENTS TO EVALUATE PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF

Media Contacts

GORE^® TAG^® THORACIC BRANCH ENDOPROSTHESIS (TBE) NOW INDICATED FOR ZONE 0 AND ZONE 1 AORTIC ARCH REPAIRS

FIRST COMMERCIAL IMPLANT OF THE GORE^® EXCLUDER^® CONFORMABLE AAA ENDOPROSTHESIS WITH ACTIVE CONTROL SYSTEM IN CANADA

Gore releases 3-year data for the GORE^® CARDIOFORM ASD Occluder

W. L. GORE & ASSOCIATES, INC. RECEIVES U.S. FOOD & DRUG ADMINISTRATION (FDA) APPROVAL FOR LOWER PROFILE GORE^® VIABAHN^® VBX BALLOON EXPANDABLE ENDOPROSTHESIS, NOW 6 FR SHEATH COMPATIBLE

GORE ANNOUNCES FIRST PATIENT IMPLANT IN THE ARISE II PIVOTAL STUDY OF THE GORE^® ASCENDING STENT GRAFT